$10.98
0.27% today
Nasdaq, Feb 28, 05:21 pm CET
ISIN
US4923271013
Symbol
KROS
Sector
Industry

Keros Therapeutics Inc Stock price

$11.01
-0.44 3.84% 1M
-34.36 75.73% 6M
-4.82 30.45% YTD
-58.99 84.27% 1Y
-42.69 79.50% 3Y
-9.07 45.17% 5Y
-9.07 45.17% 10Y
Nasdaq, Closing price Thu, Feb 27 2025
+0.07 0.64%
ISIN
US4923271013
Symbol
KROS
Sector
Industry

Key metrics

Market capitalization $445.99m
Enterprise Value $-95.08m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF 0.58
EV/Sales (TTM) EV/Sales -26.78
P/S ratio (TTM) P/S ratio 125.63
P/B ratio (TTM) P/B ratio 0.78
Revenue growth (TTM) Revenue growth 2,250.99%
Revenue (TTM) Revenue $3.55m
EBIT (operating result TTM) EBIT $-210.83m
Free Cash Flow (TTM) Free Cash Flow $-162.80m
Cash position $559.93m
EPS (TTM) EPS $-5.01
P/E forward negative
P/S forward 332.83
EV/Sales forward negative
Short interest 14.32%
Show more

Is Keros Therapeutics Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,809 stocks worldwide.

Keros Therapeutics Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

14 Analysts have issued a Keros Therapeutics Inc forecast:

9x Buy
64%
5x Hold
36%

Analyst Opinions

14 Analysts have issued a Keros Therapeutics Inc forecast:

Buy
64%
Hold
36%

Financial data from Keros Therapeutics Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
3.55 3.55
2,267% 2,267%
100%
- Direct Costs 1.23 1.23
39% 39%
35%
2.32 2.32
223% 223%
65%
- Selling and Administrative Expenses 38 38
24% 24%
1,079%
- Research and Development Expense 174 174
28% 28%
4,891%
-210 -210
25% 25%
-5,904%
- Depreciation and Amortization 1.23 1.23
39% 39%
35%
EBIT (Operating Income) EBIT -211 -211
24% 24%
-5,939%
Net Profit -187 -187
22% 22%
-5,277%

In millions USD.

Don't miss a Thing! We will send you all news about Keros Therapeutics Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Keros Therapeutics Inc Stock News

Neutral
GlobeNewsWire
2 days ago
LEXINGTON, Mass., Feb. 26, 2025 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta (“TGF-ß”) family of proteins, today provid...
Neutral
GlobeNewsWire
29 days ago
LEXINGTON, Mass., Jan. 30, 2025 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta (“TGF-ß”) family of proteins, today announced that Keros' C...
Neutral
GlobeNewsWire
about one month ago
NEW YORK, Jan. 24, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Keros Therapeutics, Inc. (“Keros” or the “Company”) (NASDAQ:KROS) on behalf of Keros stockholders. Our investigation concerns whether Keros has violated the federal securities laws and/or engaged in other unlawful business practi...
More Keros Therapeutics Inc News

Company Profile

Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need. The company's lead protein therapeutic product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis. It is also developing small molecule product candidate KER-047 that is being developed for the treatment of anemia, as well as for the treatment of fibrodysplasia ossificans progressiva, or FOP, and is currently in a Phase 1 clinical trial; and KER-012 being developed for the treatment of disorders associated with bone loss, such as osteoporosis and osteogenesis imperfecta, and for the treatment of pulmonary arterial hypertension, or PAH. The company was founded in 2015 and is headquartered in Lexington, Massachusetts.

Head office United States
CEO Jasbir Seehra
Employees 169
Founded 2015
Website www.kerostx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today